(0.14%) 5 162.00 points
(0.15%) 38 889 points
(0.10%) 18 018 points
(0.82%) $78.75
(0.51%) $2.15
(0.63%) $2 323.10
(2.22%) $27.28
(0.20%) $967.20
(0.02%) $0.929
(-0.16%) $10.86
(-0.10%) $0.796
(0.16%) $91.60
@ $83.11
Utstedt: 1 mai 2024 @ 21:32
Avkastning: -0.80%
Forrige signal: apr 30 - 21:32
Forrige signal:
Avkastning: 2.70 %
Live Chart Being Loaded With Signals
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...
Stats | |
---|---|
Dagens volum | 1.63M |
Gjennomsnittsvolum | 1.58M |
Markedsverdi | 15.65B |
EPS | $0 ( 2024-04-24 ) |
Neste inntjeningsdato | ( $0.570 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 77.77 |
ATR14 | $2.27 (2.76%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Bienaime Jean Jacques | Buy | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
INSIDER POWER |
---|
25.83 |
Last 93 transactions |
Buy: 972 265 | Sell: 563 201 |
Volum Korrelasjon
Biomarin Pharmaceutical Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
MMAC | 0.923 |
RMRM | 0.916 |
FREQ | 0.89 |
ABST | 0.889 |
IMPL | 0.889 |
TTOO | 0.887 |
SGBX | 0.887 |
INFI | 0.885 |
SBBP | 0.884 |
CFV | 0.884 |
10 Mest negative korrelasjoner | |
---|---|
APOP | -0.956 |
ICON | -0.907 |
RDUS | -0.893 |
MIND | -0.88 |
TRMD | -0.879 |
WRLD | -0.878 |
SYKE | -0.875 |
BNIXU | -0.873 |
SOUN | -0.873 |
MGTX | -0.873 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Biomarin Pharmaceutical Korrelasjon - Valuta/Råvare
Biomarin Pharmaceutical Økonomi
Annual | 2023 |
Omsetning: | $2.42B |
Bruttogevinst: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2023 |
Omsetning: | $2.42B |
Bruttogevinst: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2022 |
Omsetning: | $2.10B |
Bruttogevinst: | $1.61B (76.92 %) |
EPS: | $0.760 |
FY | 2021 |
Omsetning: | $1.85B |
Bruttogevinst: | $1.38B (74.52 %) |
EPS: | $-0.354 |
Financial Reports:
No articles found.
Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.